Liquidia Technologies: Legal Wins and Promising Clinical Data Bolster Buy Rating

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Liquidia Technologies (LQDA – Research Report), with a price target of $29.00.

Andrew Fein has given his Buy rating due to a combination of factors surrounding Liquidia Technologies’ potential market opportunities and legal advancements. With the upcoming PDUFA date for Yutrepia on May 24, 2025, the company is poised for a significant market entry into both pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The recent dismissal of United Therapeutics’ cross-claim has removed a major legal hurdle, clearing the path for FDA decision-making and enhancing Liquidia’s prospects.
Furthermore, the emerging clinical data from the ASCENT study highlights Yutrepia’s superior performance compared to Tyvaso DPI, particularly in PH-ILD. The study’s interim results demonstrate a significant improvement in patients’ conditions, with a wider therapeutic window and no serious adverse events reported. This clinical differentiation, coupled with the favorable legal developments, underpins Fein’s confidence in Liquidia’s potential to capture market share and supports his Buy rating.

In another report released on May 9, Scotiabank also maintained a Buy rating on the stock with a $36.00 price target.